Dr. Guo has conducted biomedical research for more than 15 years, with excellent research experience in cell phenotypic regulation, gene transcriptional regulation, screening of signaling pathways/factors that mediate gene function, and generation of conditional knockout mice to examine the biological function of genes in specific tissues using animal models. Dr. Guo received her PhD in Physiology and Pharmacology at the University of Georgia in 2014. After graduation, she worked as a postdoctoral fellow and scientist in the Department of Physiology and Pharmacology at the University of Georgia. In 2019, Dr. Guo joined the University of Texas Health Science Center at Tyler as an Assistant Professor in the Department of Cellular and Molecular Biology. She has published over 30 peer-reviewed papers in journals including Circulation Research, Arterioscler Thromb Vasc Biol. (ATVB), and Journal of Hepatology. Dr. Guo is also an active member of American Heart Association (AHA) since 2012. Dr. Guo’s research program has been continuously funded by the American Heart Association (AHA) and National Institutes of Health (NIH) since 2012.
Education & Training
Dr. Guo’s research broadly focuses on understanding the novel molecules and mechanisms important for cardiovascular disease and/or metabolic disease development. These molecules may contribute to the prevention and/or generation of therapeutics of these human diseases. Specifically, we study 1) the vascular smooth muscle cell (SMC), endothelial cell (EC), and immune cell phenotypic change during the cardiovascular disease development including atherosclerosis, abdominal aortic aneurysm (AAA), hypertension, restenosis and so on; 2) the adipocyte, liver cell, and immune cell phenotypic change during the metabolic disease development including obesity, diabetes, hepatic steatosis and the related complications. Our laboratory uses multiple, cutting-edge approaches to identify novel targets and develop gene/cell-based therapeutics to treat these human problems.
Qian G, Adeyanju O, Cai D, Tucker TA, Idell S, Chen S-Y, and Guo X. DOCK2 promotes atherosclerosis through mediating vascular endothelial cell inflammation. Am J Pathol. 2023 Oct 12:S0002-9440(23)00377-2.
Guo X*, Cai D, Dong K, Li C, Xu Z, and Chen S-Y*. Deficiency Attenuates Abdominal Aortic Aneurysm Formation. Arterioscler Thromb Vasc Biol. 2023 Jun;43(6):e210-e217. (*, co-corresponding)
Guo X, Adeyanju O, S Olajuyin A, Mandlem V, Sunil C, Huang S, Tucker TA, Idell S, and Qian G. MARCH8 downregulation modulates profibrotic responses including myofibroblast differentiation. Am J Physiol - Cell Physiol. 2023 Nov 1;325(5):C1190-C1200.
Guo X, Adeyanju O, Sunil C, Mandlem V, Olajuyin A, Huang S, Chen SY, Idell S, Tucker TA, and Qian G. DOCK2 contributes to pulmonary fibrosis by promoting lung fibroblast to myofibroblast transition. Am J Physiol Cell Physiol. 2022. 323(1):C133-C144.
Qian G, Adeyanju O, Sunil C, Huang SK, Chen SY, Tucker TA, Idell S, and Guo X. Dedicator of Cytokinesis 2 (DOCK2) Deficiency Attenuates Lung Injury Associated with Chronic High-Fat and High-Fructose Diet-Induced Obesity. Am J Pathol. 2022 Feb;192(2):226-238.
Qian G, Adeyanju O, Roy S, Sunil C, Jeffers A, Guo X, Ikebe M, Idell S, and Tucker TA. DOCK2 Promotes Pleural Fibrosis by Modulating Mesothelial to Mesenchymal Transition. Am J Respir Cell Mol Biol. 2022 Feb;66(2):171-182.
Guo X, Li FF, Xu Z, Yin A, Yin H, Li C, and Chen SY. (2017). DOCK2 deficiency mitigates HFD-induced obesity by reducing adipose tissue inflammation and increasing energy expenditure. J Lipid Res. Sep;58(9):1777-1784.
Guo X, Shi N, Cui XB, Wang JN, Fukui Y, and Chen SY. (2015). Dedicator of cytokinesis 2, a novel regulator for smooth muscle phenotypic modulation and vascular remodeling. Circ Res. 116(10):e71-80.
Cui XB, Guo X, Chen SY. (2013). Response gene to complement 32-deficiency causes impaired placental angiogenesis in mice. Cardiovasc Res, 99(4):632-9.
- Assistant Research Scientist, The University of Georgia, 2019
- Postdoctoral Fellow, The University of Georgia, 2018
- PhD, The University of Georgia, Physiology and Pharmacology, 2014
- BIOT5222/BIOT5222L - Advanced Metabolism/Lab
- BIOT 6311 - Biotechnology I
- BIOT 5310 - Fundamentals of Biomedical Research
Dr. Guo’s research broadly focuses on understanding the novel molecules and mechanisms important for cardiovascular disease and/or metabolic disease development. These molecules may contribute to the prevention and/or generation of therapeutics of these human diseases. Specifically, we study 1) the vascular smooth muscle cell (SMC), endothelial cell (EC), and immune cell phenotypic change during the cardiovascular disease development including atherosclerosis, abdominal aortic aneurysm (AAA), hypertension, restenosis and so on; 2) the adipocyte, liver cell, and immune cell phenotypic change during the metabolic disease development including obesity, diabetes, hepatic steatosis and the related complications. Our laboratory uses multiple, cutting-edge approaches to identify novel targets and develop gene/cell-based therapeutics to treat these human problems.
- Vascular smooth muscle cell differentiation
- Vascular smooth muscle cell phenotypic modulation in vascular remodeling
- Endothelial cell inflammation and macrophage activation in atherosclerosis
- Epithelial-mesenchymal transition (EMT) in disease development
- Metabolic diseases including obesity, diabetes, and hepatic steatosis
Qian G, Adeyanju O, Cai D, Tucker TA, Idell S, Chen S-Y, and Guo X. DOCK2 promotes atherosclerosis through mediating vascular endothelial cell inflammation. Am J Pathol. 2023 Oct 12:S0002-9440(23)00377-2.
Guo X*, Cai D, Dong K, Li C, Xu Z, and Chen S-Y*. Deficiency Attenuates Abdominal Aortic Aneurysm Formation. Arterioscler Thromb Vasc Biol. 2023 Jun;43(6):e210-e217. (*, co-corresponding)
Guo X, Adeyanju O, S Olajuyin A, Mandlem V, Sunil C, Huang S, Tucker TA, Idell S, and Qian G. MARCH8 downregulation modulates profibrotic responses including myofibroblast differentiation. Am J Physiol - Cell Physiol. 2023 Nov 1;325(5):C1190-C1200.
Guo X, Adeyanju O, Sunil C, Mandlem V, Olajuyin A, Huang S, Chen SY, Idell S, Tucker TA, and Qian G. DOCK2 contributes to pulmonary fibrosis by promoting lung fibroblast to myofibroblast transition. Am J Physiol Cell Physiol. 2022. 323(1):C133-C144.
Qian G, Adeyanju O, Sunil C, Huang SK, Chen SY, Tucker TA, Idell S, and Guo X. Dedicator of Cytokinesis 2 (DOCK2) Deficiency Attenuates Lung Injury Associated with Chronic High-Fat and High-Fructose Diet-Induced Obesity. Am J Pathol. 2022 Feb;192(2):226-238.
Qian G, Adeyanju O, Roy S, Sunil C, Jeffers A, Guo X, Ikebe M, Idell S, and Tucker TA. DOCK2 Promotes Pleural Fibrosis by Modulating Mesothelial to Mesenchymal Transition. Am J Respir Cell Mol Biol. 2022 Feb;66(2):171-182.
Guo X, Li FF, Xu Z, Yin A, Yin H, Li C, and Chen SY. (2017). DOCK2 deficiency mitigates HFD-induced obesity by reducing adipose tissue inflammation and increasing energy expenditure. J Lipid Res. Sep;58(9):1777-1784.
Guo X, Shi N, Cui XB, Wang JN, Fukui Y, and Chen SY. (2015). Dedicator of cytokinesis 2, a novel regulator for smooth muscle phenotypic modulation and vascular remodeling. Circ Res. 116(10):e71-80.
Cui XB, Guo X, Chen SY. (2013). Response gene to complement 32-deficiency causes impaired placental angiogenesis in mice. Cardiovasc Res, 99(4):632-9.